• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Sera Prognostics Inc.

    3/19/25 4:19:27 PM ET
    $SERA
    Medical Specialities
    Health Care
    Get the next $SERA alert in real time by email
    S-8 1 sera-20250318.htm S-8 S-8

     

     

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    Sera Prognostics, Inc.

    (Exact name of registrant as specified in its charter)

    Delaware

     

    26-1911522

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    2749 East Parleys Way

    Suite 200
    Salt Lake City, UT 84109

    Telephone: (801) 990-0520

    (Address, including zip code, and telephone number, including area code,

    of registrant’s principal executive offices)

    2021 Equity Incentive Plan

    2021 Employee Stock Purchase Plan

    (Full Title of the Plans)

    Zhenya Lindgardt

    President and Chief Executive Officer

    Sera Prognostics, Inc.

    2749 East Parleys Way

    Suite 200

    Salt Lake City, UT 84109

    Telephone: (801) 990-0520

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    o

    Accelerated filer

    o

    Non-accelerated filer

    x

    Smaller reporting company

    x

     

     

    Emerging growth company

    x

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

    EXPLANATORY NOTE

    This Registration Statement registers 1,328,276 additional shares of Class A Common Stock, par value $0.0001 per share (“Common Stock”), of Sera Prognostics, Inc. (the “Registrant”) under the Registrant’s 2021 Equity Incentive Plan (the “2021 Plan”) and 332,069 additional shares of Common Stock under the Registrant’s 2021 Employee Stock Purchase Plan (the “ESPP”), representing an increase of 1,328,276 shares of Common Stock reserved for issuance under the 2021 Plan and 332,069 shares of Common Stock reserved for issuance under the ESPP, in each case effective January 1, 2025 by operation of the “evergreen” provision contained in the applicable plan. This Registration Statement registers additional securities of the same class as other securities for which a registration statement filed on Form S-8 of the Registrant relating to one or more employee benefit plans is effective (File Nos. 333-258696, 333-263943, 333-270746, and 333-278104) (the “Prior Registration Statements”). The information contained in the Registrant’s Prior Registration Statements is hereby incorporated by reference pursuant to General Instruction E of Form S-8.

    2


     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits

    Exhibit Number

     

    Exhibit Description

     

    Filed Herewith

     

    Incorporated by Reference herein from Form or Schedule

     

    Filing Date

     

    SEC File/Reg. Number

    4.1.1

     

    Amended and Restated Certificate of Incorporation

     

     

     

    Form 8-K (Exhibit 3.1)

     

    7/20/2021

     

    001-40606

    4.1.2

     

    Certificate of Amendment to Amended and Restated Certificate of Incorporation

     

     

     

    Form 8-K (Exhibit 3.1)

     

    6/9/2023

     

    001-40606

    4.2

     

    Amended and Restated Bylaws

     

     

     

    Form 8-K (Exhibit 3.2)

     

    7/20/2021

     

    001-40606

    4.3

     

    Specimen Common Stock Certificate

     

     

     

    Form S-1/A (Exhibit 4.1)

     

    7/8/2021

     

    333-257038

    4.4

     

    Form of Common Stock Purchase Warrant - I

     

     

     

    Form S-1 (Exhibit 4.2)

     

    6/11/2021

     

    333-257038

    4.5

     

    Form of Common Stock Purchase Warrant - II

     

     

     

    Form S-1 (Exhibit 4.3)

     

    6/11/2021

     

    333-257038

    4.6

     

    Form of Series E Warrant

     

     

     

    Form S-1 (Exhibit 4.4)

     

    6/11/2021

     

    333-257038

    4.7

     

    Fourth Amended and Restated Investors’ Rights Agreement, dated as of February 23, 2021

     

     

     

    Form S-1 (Exhibit 4.5)

     

    6/11/2021

     

    333-257038

    4.8

     

    Form of Pre-Funded Warrant

     

     

     

    Form 8-K (Exhibit 4.1)

     

    2/12/2025

     

    001-40606

    5.1

     

    Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

     

    X

     

     

     

     

     

     

    23.1

     

    Consent of Independent Registered Public Accounting Firm

     

    X

     

     

     

     

     

     

    23.2

     

    Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1)

     

    X

     

     

     

     

     

     

    24.1

     

    Power of Attorney (included on the signature page hereof)

     

    X

     

     

     

     

     

     

    99.1+

     

    2021 Equity Incentive Plan

     

     

     

    Form S-1/A (Exhibit 10.3)

     

    7/8/2021

     

    333-257038

    99.2+

     

    Form of Stock Option Agreement under the Registrant’s 2021 Equity Incentive Plan

     

     

     

    Form S-1/A (Exhibit 10.3)

     

    7/8/2021

     

    333-257038

    99.3+

     

    Form of Restricted Stock Unit Agreement under the Registrant’s 2021 Equity Incentive Plan

     

     

     

    Form 10-K (Exhibit 10.29)

     

    3/20/2024

     

    001-40606

    99.4+

     

    2021 Employee Stock Purchase Plan

     

     

     

    Form S-1/A (Exhibit 10.4)

     

    7/8/2021

     

    333-257038

    107

     

    Filing Fee Table

     

    X

     

     

     

     

     

     

    __________________________________

    + Denotes management contract or compensatory plan or arrangement

    3


     

    Signatures

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized in Salt Lake City, Utah, on the 19th day of March, 2025.

    SERA PROGNOSTICS, INC.

    By: /s/ Zhenya Lindgardt

    Zhenya Lindgardt

    President and Chief Executive Officer

    POWER OF ATTORNEY

    Each person whose signature appears below constitutes and appoints each of Zhenya Lindgardt and Austin Aerts, acting alone or together with another attorney-in-fact, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

    Signature

     

    Title

     

    Date

     

     

     

     

     

    /s/ Zhenya Lindgardt

     

    President and Chief Executive Officer (Principal Executive Officer)

     

    March 19, 2025

    Zhenya Lindgardt

     

     

     

     

     

     

     

    /s/ Austin Aerts

     

    Chief Financial Officer (Principal Financial and Accounting Officer)

     

    March 19, 2025

    Austin Aerts

     

     

     

     

     

    /s/ Kim Kamdar, Ph.D.

     

    Chair of the Board of Directors

     

    March 19, 2025

    Kim Kamdar, Ph.D.

     

     

     

     

     

    /s/ Jane F. Barlow, M.D.

     

    Director

     

     

    March 19, 2025

    Jane F. Barlow, M.D.

     

     

     

     

     

    /s/ Gregory C. Critchfield, M.D., M.S.

     

    Director

     

     

    March 19, 2025

    Gregory C. Critchfield, M.D., M.S.

     

     

     

     

     

    /s/ Sandra A.J. Lawrence

     

    Director

     

     

    March 19, 2025

    Sandra A.J. Lawrence

     

     

     

     

     

    /s/ Mansoor Raza Mirza, M.D.

     

    Director

     

     

    March 19, 2025

    Mansoor Raza Mirza, M.D.

     

     

     

     

     

    /s/ Joshua Phillips

     

    Director

     

     

    March 19, 2025

    Joshua Phillips

     

     

     

     

     

     

     

    /s/ Ryan Trimble

     

    Director

     

     

    March 19, 2025

    Ryan Trimble

     

     

     

     

     

     

     

    /s/ Marcus Wilson, Pharm.D.

     

    Director

     

     

    March 19, 2025

    Marcus Wilson, Pharm.D.

     

     

     

    4


    Get the next $SERA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SERA

    DatePrice TargetRatingAnalyst
    3/30/2022$18.00 → $4.00Buy → Neutral
    Citigroup
    11/19/2021$19.00Outperform
    Oppenheimer
    10/15/2021Outperform
    Cowen
    8/9/2021Outperform
    William Blair
    8/9/2021Outperform
    Cowen
    8/9/2021$18.00Buy
    Citigroup
    More analyst ratings

    $SERA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mirza Mansoor Raza sold $259 worth of shares (106 units at $2.44), decreasing direct ownership by 0.24% to 43,672 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:18:31 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Chief Executive Officer Lindgardt Zhenya sold $22,951 worth of shares (9,406 units at $2.44), decreasing direct ownership by 1% to 867,251 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:18:14 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Chief Data Officer Kearney Paul sold $17,297 worth of shares (7,089 units at $2.44), decreasing direct ownership by 3% to 196,711 units (SEC Form 4)

      4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

      5/9/25 7:17:53 PM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    Financials

    Live finance-specific insights

    See more
    • SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

      SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights: Following release of full Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study results meeting primary success criteria, Sera is elevating engagement with payors and plan administrat

      5/7/25 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2025 Financial Results on May 7, 2025

      SALT LAKE CITY, April 24, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2025 financial results on Wednesday, May 7, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

      4/24/25 8:30:00 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: On January 6, 2025, the Society for Maternal Fetal Medicine ("SMFM") published an abstract reporting topline results for Sera's Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PR

      3/19/25 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    SEC Filings

    See more

    $SERA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SERA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SERA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 144 filed by Sera Prognostics Inc.

      144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      5/9/25 7:20:09 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form 144 filed by Sera Prognostics Inc.

      144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      5/9/25 7:19:32 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)

      5/8/25 5:20:29 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Sera Prognostics downgraded by Citigroup with a new price target

      Citigroup downgraded Sera Prognostics from Buy to Neutral and set a new price target of $4.00 from $18.00 previously

      3/30/22 7:52:32 AM ET
      $SERA
      Medical Specialities
      Health Care
    • Oppenheimer initiated coverage on Sera Prognostics with a new price target

      Oppenheimer initiated coverage of Sera Prognostics with a rating of Outperform and set a new price target of $19.00

      11/19/21 4:55:47 AM ET
      $SERA
      Medical Specialities
      Health Care
    • Cowen resumed coverage on Sera Prognostics

      Cowen resumed coverage of Sera Prognostics with a rating of Outperform

      10/15/21 7:31:16 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

      SALT LAKE CITY, May 29, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that members of the Sera team will participate in the following upcoming investor conferences: William Blair 45th Annual Growth Stock ConferenceDate: June 3 – 5, 20251X1 Meetings OnlyDoug Fisher, M.D., Strategic Advisor to Sera and former Chief Business Officer, will participate in meetings on Wednesday, June 4, 2025. Jefferies

      5/29/25 8:30:00 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCE

      SALT LAKE CITY , May 14, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the RBC Global Healthcare Conference on Wednesday, May 21, 2025, from 9:30 – 9:55 a.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss the company's latest achievements. A live webcast of the company's presentation as well as

      5/14/25 4:05:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER

      Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.

      5/8/25 4:40:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

      SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      11/14/24 5:46:12 PM ET
      $SERA
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

      SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      11/4/24 7:19:49 AM ET
      $SERA
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Sera Prognostics Inc.

      SC 13G - SERA PROGNOSTICS, INC. (0001534969) (Subject)

      4/1/24 7:33:43 PM ET
      $SERA
      Medical Specialities
      Health Care

    $SERA
    Leadership Updates

    Live Leadership Updates

    See more
    • SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER

      Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.

      5/8/25 4:40:00 PM ET
      $SERA
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

      3/19/25 4:10:00 PM ET
      $EXAS
      $QTRX
      $SERA
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO

      SALT LAKE CITY, May 15, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the retirement of the Company's President and CEO, Gregory C. Critchfield, M.D., M.S. Dr. Critchfield is retiring after 12 years of dedicated and valuable service to the Company. Dr. Critchfield plans to step down from his executive role effective June 8, 2023, to pursue other activities. Zhenya Lindgardt, a member of the Company's Board of Directors, will succeed Dr. Critchfield, as Interim CEO & President. Kim Kamdar, Ph.D., a member of the

      5/15/23 5:15:00 PM ET
      $SERA
      Medical Specialities
      Health Care